|
1
|
National Lung Screening Trial Research
Team, . Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD,
Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD:
Reduced lung-cancer mortality with low-dose computed tomographic
screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minguet J, Smith KH and Bramlage P:
Targeted therapies for treatment of non-small cell lung
cancer-Recent advances and future perspectives. Int J Cancer.
138:2549–2561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Villaruz LC and Socinski MA: Is there a
role of nab-paclitaxel in the treatment of advanced non-small cell
lung cancer? The data suggest yes. Eur J Cancer. 56:162–171. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA A Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
5
|
Yin Y, Chen W, Tang C, Ding H, Jang J,
Weng M, Cai Y and Zou G: NF-kB, JNK and p53 pathways are involved
in tubeimoside-1-induced apoptosis in HepG2 cells with oxidative
stress and G (2)/M cell cycle arrest. Food Chem Toxicol.
49:3046–3054. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gu Y, Korbel C, Scheuer C, Nenicu A,
Menger MD and Laschke MW: Tubeimoside-1 suppresses tumor
angiogenesis by stimulation of proteasomal VEGFR2 and Tie2
degradation in a non-small cell lung cancer xenograft model.
Oncotarget. 7:5258–5272. 2016.PubMed/NCBI
|
|
7
|
Bian Q, Liu P, Gu J and Song B:
Tubeimoside-1 inhibits the growth and invasion of colorectal cancer
cells through the Wnt/β-catenin signaling pathway. Int J Clin.
8:12517–12524. 2015.
|
|
8
|
Hao W, Wang S and Zhou Z: Tubeimoside-1
(TBMS1) inhibits lung cancer cell growth and induces cells
apoptosis through activation of MAPK-JNK pathway. Int J Clin Exp
Pathol. 8:12075–12083. 2015.PubMed/NCBI
|
|
9
|
Lin Y, Xie G, Xia J, Su D, Liu J, Jiang F
and Xu Y: TBMS1 exerts its cytotoxicity in NCI-H460 lung cancer
cells through nucleolar stress-induced p53/MDM2-dependent
mechanism, a quantitative proteomics study. Biochim Biophys Acta.
1864:204–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia G, Wang Q, Wang R, Deng D, Xue L, Shao
N, Zhang Y, Xia X, Zhi F and Yang Y: Tubeimoside-1 induces glioma
apoptosis through regulation of Bax/Bcl-2 and the ROS/Cytochrome
C/Caspase-3 pathway. Onco Targets Ther. 8:303–311. 2015.PubMed/NCBI
|
|
11
|
Zhang Y, Xu XM, Zhang M, Qu D, Niu HY, Bai
X, Kan L and He P: Effects of tubeimoside-1 on the proliferation
and apoptosis of BGC823 gastric cancer cells in vitro. Oncol Lett.
5:801–804. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weng XY, Ma RD and Yu LJ: Apoptosis of
human nasopharyngeal carcinoma CNE-2Z cells induced by tubeimoside
I. Ai Zheng. 22:806–811. 2003.PubMed/NCBI
|
|
13
|
Peng Y, Zhong Y and Li G: Tubeimoside-1
suppresses breast cancer metastasis through downregulation of CXCR4
chemokine receptor expression. BMB Rep. 49:502–507. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ni N, Zhang D, Xie Q, Chen J, Wang Z, Deng
Y, Wen X, Zhu M, Ji J, Fan X, et al: Effects of let-7b and TLX on
the proliferation and differentiation of retinal progenitor cells
in vitro. Sci Rep. 4:66712014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu M, Sun L, Zhou J, Zhao Y and Deng X:
Dihydroartemi-sinin-induced apoptosis is associated with inhibition
of sarco/endoplasmic reticulum calcium ATPase activity in
colorectal cancer. Cell Biochem Biophys. 73:137–145. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shan S, Lv Q, Zhao Y, Liu C, Sun Y, Xi K,
Xiao J and Li C: Wnt/β-catenin pathway is required for epithelial
to mesenchymal transition in CXCL12 over expressed breast cancer
cells. Int J Clin Exp Pathol. 8:12357–12367. 2015.PubMed/NCBI
|
|
17
|
Ricciuti B, Mecca C, Crino L, Baglivo S,
Cenci M and Metro G: Non-coding RNAs in lung cancer. Oncoscience.
1:674–705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singla AK, Downey CM, Bebb GD and Jirik
FR: Characterization of a murine model of metastatic human
non-small cell lung cancer and effect of CXCR4 inhibition on the
growth of metastases. Oncoscience. 2:263–271. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu W, Bi C, Credille KM, Manro JR, Peek
VL, Donoho GP, Yan L, Wijsman JA, Yan SB and Walgren RA: Inhibition
of tumor growth and metastasis in non-small cell lung cancer by
LY2801653, an inhibitor of several oncokinases, including MET. Clin
Cancer Res. 19:5699–5710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meister J and Schmidt MH: miR-126 and
miR-126*: New players in cancer. Sci World J. 10:2090–2100. 2010.
View Article : Google Scholar
|
|
21
|
Shibayama Y, Kondo T, Ohya H, Fujisawa S,
Teshima T and Iseki K: Upregulation of microRNA-126-5p is
associated with drug resistance to cytarabine and poor prognosis in
AML patients. Oncol Rep. 33:2176–2182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Musiyenko A, Bitko V and Barik S: Ectopic
expression of miR-126*, an intronic product of the vascular
endothelial EGF-like 7 gene, regulates prostein translation and
invasiveness of prostate cancer LNCaP cells. J Mol Med (Berl).
86:313–322. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Felli N, Felicetti F, Lustri AM, Errico
MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F,
Biffoni M, et al: miR-126&126* restored expressions play a
tumor suppressor role by directly regulating ADAM9 and MMP7 in
melanoma. PLoS One. 8:e568242013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y,
Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and miR-126*
repress recruitment of mesenchymal stem cells and inflammatory
monocytes to inhibit breast cancer metastasis. Nat Cell Biol.
15:284–294. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sanfiorenzo C, Ilie MI, Belaid A, Barlési
F, Mouroux J, Marquette CH, Brest P and Hofman P: Two panels of
plasma microRNAs as non-invasive biomarkers for prediction of
recurrence in resectable NSCLC. PLoS One. 8:e545962013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vosa U, Vooder T, Kolde R, Vilo J,
Metspalu A and Annilo T: Meta-analysis of microRNA expression in
lung cancer. Int J Cancer. 132:2884–2893. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoshiji H, Gomez DE, Shibuya M and
Thorgeirsson UP: Expression of vascular endothelial growth factor,
its receptor and other angiogenic factors in human breast cancer.
Cancer Res. 56:2013–2016. 1996.PubMed/NCBI
|
|
28
|
Volm M, Koomägi R and Mattern J:
Prognostic value of vascular endothelial growth factor and its
receptor Flt-1 in squamous cell lung cancer. Int J Cancer.
74:64–68. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hatva E, Kaipainen A, Mentula P,
Jääskeläinen J, Paetau A, Haltia M and Alitalo K: Expression of
endothelial cell-specific receptor tyrosine kinases and growth
factors in human brain tumors. Ame J Pathol. 146:368–378. 1995.
|
|
30
|
Ellis LM, Takahashi Y, Fenoglio CJ, Cleary
KR, Bucana CD and Evans DB: Vessel counts and vascular endothelial
growth factor expression in pancreatic adenocarcinoma. Eur J
Cancer. 34:337–340. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boocock CA, Charnock-Jones DS, Sharkey AM,
McLaren J, Barker PJ, Wright KA, Twentyman PR and Smith SK:
Expression of vascular endothelial growth factor and its receptors
flt and KDR in ovarian carcinoma. J Natil Cancer Inst. 87:506–516.
1995. View Article : Google Scholar
|
|
32
|
Brown LF, Berse B, Jackman RW, Tognazzi K,
Manseau EJ, Dvorak HF and Senger DR: Increased expression of
vascular permeability factor (vascular endothelial growth factor)
and its receptors in kidney and bladder carcinomas. Am J Pathol.
143:1255–1262. 1993.PubMed/NCBI
|
|
33
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu B, Peng XC, Zheng XL, Wang J and Qin
YW: MiR-126 restoration down-regulate VEGF and inhibit the growth
of lung cancer cell lines in vitro and in vivo. Lung Cancer.
66:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang R, Pei L, Bai T and Wang J:
Down-regulation of microRNA-126-5p contributes to overexpression of
VEGFA in lipopolysaccharide-induced acute lung injury. Biotechnol
Lett. 38:1277–1284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Matsumoto K and Ema M: Roles of VEGF-A
signalling in development, regeneration and tumours. J Biochem.
156:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Santos SC and Dias S: Internal and
external autocrine VEGF/KDR loops regulate survival of subsets of
acute leukemia through distinct signaling pathways. Blood.
103:3883–3889. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tian Y, Xie Q, Tian Y, Liu Y, Huang Z, Fan
C, Hou B, Sun D, Yao K and Chen T: Radioactive 125I seed
inhibits the cell growth, migration and invasion of nasopharyngeal
carcinoma by triggering DNA damage and inactivating VEGF-A/ERK
signaling. PLoS One. 8:e740382013. View Article : Google Scholar : PubMed/NCBI
|
